688393 Guangzhou LBP Medicine Science & Technology
- 18.28
- +0.09+0.49%
Guangzhou LBP Medicine Science & Technology News
Anbipine (688393.SH): No technology related to human stem cells yet
Gelonghui, May 10丨An Biping (688393.SH) said on the interactive platform that the company's main business includes cancer screening and accurate diagnosis, mainly for hospital pathology departments, and has not yet involved human stem cell-related technology.
Chinese Drug Regulator Grants Certificates to Two LBP Medicine Science & Technology Products
Guangzhou LBP Medicine Science & Technology (SHA:688393) obtained a medical device registration certificate from China's National Medical Products Administration for two products, according to the com
Anbiping (688393.SH) obtained medical device registration certificate for 2 in vitro diagnostic reagents
Anbiping (688393.SH) announced that the company recently received the “Medical Device Registration Certificate (In Vitro Diagnostic Reagent)” issued by the State Drug Administration. The product names are progesterone receptor antibody reagent (immunohistochemistry) and estrogen receptor antibody reagent (immunohistochemistry). According to reports, the above reagents can be used in combination with the company's existing HER2 antibody reagents (immunohistochemistry) and HER2 genetic test kits (fluorescence in situ hybridization) to provide a more complete breast cancer testing package, which is conducive to expanding the company's product layout in the field of tumor screening and accurate diagnosis.
Express News | An Biping: Recently received a medical device registration certificate issued by the State Drug Administration
Anbiping (688393.SH)'s net profit of 7.99 million yuan in the first quarter increased 2.17% year over year
Gelonghui, April 29丨An Biping (688393.SH) announced that in the first quarter of 2024, the company's revenue was 101 million yuan, up 11.82% year on year; net profit attributable to shareholders of listed companies was 7.99 million yuan, up 2.17% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4.8 million yuan, up 78.59% year on year.
Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Shareholders Have More To Worry About Than Only Soft Earnings
The market rallied behind Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareh
LBP Medicine Scraps Convertible Bonds Issuance Plans
Guangzhou LBP Medicine Science & Technology (SHA:688393) withdrew plans to issue convertible bonds, the company said in its filing on the Shanghai Stock Exchange. The Chinese diagnostic product manufa
An Biping (688393.SH): Net profit in 2023 fell 6.18% year on year, and plans to pay 10 to 1.5 yuan
Gelonghui, April 22丨An Biping (688393.SH) released its 2023 annual report. Operating revenue for the reporting period was 497 million yuan, down 1.99% year on year; net profit attributable to shareholders of listed companies was 40.572 million yuan, down 6.18% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 353.13,800 yuan, down 13.74% year on year; basic earnings per share were 0.43 yuan. The company plans to distribute a cash dividend of 1.5 yuan (tax included) for every 10 shares to all shareholders.
LBP Medicine Gets Certificate for HER2 Antibody Reagent
Guangzhou LBP Medicine Science & Technology (SHA:688393) received a device registration certificate for its HER2 antibody reagent from China's National Medical Products Administration, according to th
Anbiping: Obtaining a medical device registration certificate for HER2 antibody reagents
An Biping announced on the evening of April 18 that the company recently received a “Medical Device Registration Certificate” for the HER2 antibody reagent issued by the State Drug Administration. This reagent is an immunohistochemical platform used to qualitatively detect HER2 antigen in breast cancer patients, and a registration certificate for trastuzumab concomitant diagnostic testing.
Anbiping (688393.SH) received the HER2 antibody reagent (immunohistochemistry) medical device registration certificate
Anbiping (688393.SH) issued an announcement. The company recently received the “Medical Device Registration Certificate (in vitro diagnostic reagent)” issued by the State Drug Administration. The product name is HER2 antibody reagent (immunohistochemistry). This reagent is an immunohistochemical platform used to qualitatively detect HER2 antigen in breast cancer patients and a registration certificate for trastuzumab (hercetin). Joint use with the company's existing HER2 genetic test kit (fluorescence in situ hybridization) meets the requirements of the testing guidelines, making the company the only domestic manufacturer that can provide dual technology testing and use of HER2 pathology for breast cancer
Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) Shares Climb 30% But Its Business Is Yet to Catch Up
Those holding Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) shares would be relieved that the share price has rebounded 30% in the last thirty days, but it needs to keep going to
Anbiping (688393.SH) products obtained medical device registration certificate
Anbiping (688393.SH) announced that the company recently received “Medical Devices...” issued by the State Drug Administration
Anbiping (688393.SH) performance report: 2023 net profit of 403.01 million yuan, a year-on-year decrease of 5.61%
Gelonghui, Feb. 23: An Biping (688393.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 497.295 million yuan, a year-on-year decrease of 1.99%; realized net profit attributable to owners of the parent company of 403.01 million yuan, a year-on-year decrease of 5.61%; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses, of 36.44,800 yuan, a year-on-year decrease of 10.99%.
Risks Still Elevated At These Prices As Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Shares Dive 26%
The Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has cappe
An Biping (688393.SH): The company has been re-certified as a high-tech enterprise
Gelonghui, January 26丨An Biping (688393.SH) announced that it recently received the “Notice on Filing the Third Batch of High-tech Enterprises with 2023 Certification Report” issued by the Office of the National High-tech Enterprise Certification and Management Leading Group. According to the “Third Batch of High-tech Enterprises Filing List for 2023 Certification Report by Guangdong Certification Authority”, An Biping has passed the high-tech enterprise certification. The certificate number is: GR202344011947. The certificate number is:. The certification period is December 28, 2023, and is valid for three years. This certification is a high-tech enterprise in the Anbi Plain
Anbiping (688393.SH): The company's HPV28 full classification test kit was successfully selected for collection group A
Gelonghui January 8 丨 An Biping (688393.SH) Investor Relations Activity Record Sheet shows that the company's HPV28 full classification test kit was successfully selected for collection Group A, and we can also see that the price was drastically reduced after collection. Looking at the overall market, firstly, the reduction in the price of HPV DNA test kits will reduce the burden of medical expenses on the public, and secondly, it will bring about industry integration and purification of the business environment. We have determined that the reduction in fees is accompanied by HPV DNA testing as the initial screening method for cervical cancer. Whether it is the clinical side or the screening side for both cancers, the HPV DNA test volume will usher in another one
Anbiping (688393.SH) obtained 58 various qualifications in October-December
An Biping (688393.SH) issued an announcement. The company and its subsidiaries received domestic approval from October to December 2023...
Anbiping (688393.SH): and its subsidiary obtained 48 domestic medical device registration/filing certificates from October to December 2023
Gelonghui, January 8, 丨 An Biping (688393.SH) announced that the company and its subsidiaries obtained 48 domestic medical device registration/filing certificates and 10 intellectual property qualifications from October to December 2023.
Anbipine (688393.SH): Currently, mature cervical cytology AI products have been launched
Gelonghui, December 15|An Biping (688393.SH) said on an interactive platform that the company has been promoting the “four modernizations” of standardized, automated, digitized, and intelligent pathology departments. As part of intelligence, AI diagnosis is now a part of intelligence, and mature cervical cytology AI products have now been launched. As the cornerstone of intelligence, the construction of digitized and pathological databases is essential. The company has also been actively building products and systems in areas such as specialized disease banks, pathological information system construction, pathology data storage, and data security. Cooperation with Huawei is also part of the exploration of the above part. If there are any major developments, the company will announce them.
Analysis
Price Target
No Data
